Actinidia deliciosa Extract as a Promising Supplemental Agent for Hepatic and Renal Complication-Associated Type 2 Diabetes (In Vivo and In Silico-Based Studies).

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Actinidia* ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Experimental*/complications ; Diabetes Mellitus, Experimental*/drug therapy ; Diabetes Complications* ; Insulins*; Animals ; Rats ; Molecular Docking Simulation ; Phosphatidylinositol 3-Kinases ; Antioxidants ; Plant Extracts/pharmacology ; Plant Extracts/therapeutic use ; Mammals

Type 2 diabetes (T2D) is a chronic metabolic condition associated with obesity, oxidative stress-mediated inflammation, apoptosis, and impaired insulin signaling. The utilization of phytochemical therapy generated from plants has emerged as a promising approach for the treatment of diabetes and its complications. Kiwifruit is recognized for its substantial content of antioxidative phenolics. Therefore, this work aimed to examine the effect of Actinidia deliciosa (kiwi fruit) on hepatorenal damage in a high-fat diet (HFD) and streptozotocin (STZ)-induced T2D in rats using in vivo and in silico analyses. An increase in hepatic and renal lipid peroxidation was observed in diabetic rats accompanied by a decrease in antioxidant status. Furthermore, it is important to highlight that there were observable inflammatory and apoptotic responses in the hepatic and renal organs of rats with diabetes, along with a dysregulation of the phosphorylation levels of mammalian target of rapamycin (mTOR), protein kinase B (Akt), and phosphoinositide 3-kinase (PI3K) signaling proteins. However, the administration of kiwi extract to diabetic rats alleviated hepatorenal dysfunction, inflammatory processes, oxidative injury, and apoptotic events with activation of the insulin signaling pathway. Furthermore, molecular docking and dynamic simulation studies revealed quercetin, chlorogenic acid, and melezitose as components of kiwi extract that docked well with potential as effective natural products for activating the silent information regulator 1(SIRT-1) pathway. Furthermore, phenolic acids in kiwi extract, especially syringic acid, P-coumaric acid, caffeic acid, and ferulic acid, have the ability to inhibit the phosphatase and tensin homolog (PTEN) active site. In conclusion, it can be argued that kiwi extract may present a potentially beneficial adjunctive therapy approach for the treatment of diabetic hepatorenal complications.

Gut Microbes. 2021 Jan-Dec;13(1):1-17. (PMID: 33615993)
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89. (PMID: 6828386)
J Nutr Biochem. 2023 Sep;119:109404. (PMID: 37311491)
Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63. (PMID: 15272157)
J Biochem Mol Toxicol. 2018 Oct;32(10):e22205. (PMID: 30091233)
Anal Biochem. 1989 Nov 15;183(1):195-6. (PMID: 2619044)
Curr Issues Mol Biol. 2023 Jan 18;45(2):852-884. (PMID: 36826001)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Adv Food Nutr Res. 2013;68:273-82. (PMID: 23394993)
Nutrients. 2016 Aug 04;8(8):. (PMID: 27527213)
Nutrients. 2019 Sep 03;11(9):. (PMID: 31484373)
Chem Biol Interact. 2016 Jan 25;244:49-63. (PMID: 26656244)
Sci Rep. 2021 Oct 19;11(1):20677. (PMID: 34667196)
Nutrients. 2021 Oct 03;13(10):. (PMID: 34684501)
MedComm (2020). 2023 Jun 07;4(3):e283. (PMID: 37303813)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
Pharmacol Rep. 2016 Dec;68(6):1165-1177. (PMID: 27639595)
J Food Biochem. 2022 Jul;46(7):e14142. (PMID: 35312192)
Anal Biochem. 1997 Feb 1;245(1):55-60. (PMID: 9025968)
Pharmaceuticals (Basel). 2020 Jul 19;13(7):. (PMID: 32707662)
Crit Rev Food Sci Nutr. 2023;63(23):6491-6535. (PMID: 35164626)
Oxid Med Cell Longev. 2022 Mar 19;2022:1499510. (PMID: 35345832)
Nutrients. 2022 Aug 17;14(16):. (PMID: 36014875)
J Diabetes Metab Disord. 2023 Feb 18;22(1):721-733. (PMID: 37255787)
Front Endocrinol (Lausanne). 2022 Sep 23;13:1006376. (PMID: 36246880)
Biochim Biophys Acta. 2016 Apr;1862(4):763-777. (PMID: 26775029)
J Nutr Sci Vitaminol (Tokyo). 2020;66(Supplement):S356-S360. (PMID: 33612624)
Science. 1973 Feb 9;179(4073):588-90. (PMID: 4686466)
Pharmacol Res. 2014 Feb;80:21-35. (PMID: 24373831)
Nucleic Acids Res. 2001 May 1;29(9):e45. (PMID: 11328886)
Kidney Int. 2020 Sep;98(3):579-589. (PMID: 32739206)
Toxics. 2023 Mar 01;11(3):. (PMID: 36977005)
Nat Commun. 2022 Aug 27;13(1):5062. (PMID: 36030260)
Free Radic Biol Med. 2022 May 1;184:114-134. (PMID: 35398495)
Anal Biochem. 1981 Apr;112(2):195-203. (PMID: 6266278)
Biomed Pharmacother. 2021 Dec;144:112287. (PMID: 34649220)
Free Radic Biol Med. 1990;9(6):515-40. (PMID: 2079232)
Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
J Integr Med. 2023 May;21(3):226-235. (PMID: 36932029)
J Obes. 2022 Apr 26;2022:1015669. (PMID: 35528246)
Biochim Biophys Acta. 1979 Jan 4;582(1):67-78. (PMID: 760819)
Diabetologia. 2013 May;56(5):949-64. (PMID: 23443243)

DSR-2021-01-03182 Al Jouf University

Keywords: Actinidia deliciosa; PTEN; SIRT-1 pathway; adipocytokines; caffeic acid; insulin resistance; mTOR; melezitose

EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
0 (Antioxidants)
0 (Insulins)
0 (Plant Extracts)

Date Created: 20230928 Date Completed: 20230929 Latest Revision: 20231003

20240628

PMC10530616

10.3390/ijms241813759

37762060